TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00739492

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: financial incentives
Description: financial incentives based on attaining weight loss goals

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: financial incentives
Description: financial incentives based on attaining weight loss goals
Study: NCT01673750

Intervention type: OTHER
Intervention: Questionnaire
Description: The primary outcome, characterizing body image among HIV infected adolescents, will be measured using a questionnaire administered to study participants through Audio Computer Assisted Self-Interview (ACASI) technology.
Study: NCT01302015

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RNL-Vascostem®
Study: NCT03914300

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study: NCT02891005

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: paclitaxel controlled release balloon catheter (VasoguardTM)
Description: paclitaxel controlled release balloon catheter implantation for small vessel lesion

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: common balloon catheter (Maverick2)
Description: common balloon catheter implantation for small vessel lesion
Study: NCT03924531

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful Awareness Program
Description: 2-hour mindfulness training for 6 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Promotion Program
Description: Health Promotion Program
Study: NCT02029599

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fang yi qing feng shi granule
Description: 10g, Oral,Three each time, 3 times a day,for 3 months;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fang yi qing feng shi granule
Description: 10g, Oral,Three each time, 3 times a day,for 3 months;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: 10g, Oral,Three each time, 3 times a day,for 3 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 10g, Oral,Three each time, 3 times a day,for 3 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: 7.5-15mg per week，All patients should be used

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: 7.5-15mg per week，All patients should be used

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methotrexate
Description: 7.5-15mg per week，All patients should be used

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen tablets
Description: Oral,0.5g, 1\~2 times a day, when vas=10

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen tablets
Description: Oral,0.5g, 1\~2 times a day, when vas=10

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Acetaminophen tablets
Description: Oral,0.5g, 1\~2 times a day, when vas=10
Study: NCT00246688

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sagopilone (BAY86-5302 , ZK219477)
Description: 10.5 mg lyophilized sagopilone per vial

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sagopilone (BAY86-5302 , ZK219477)
Description: 10.5 mg lyophilized sagopilone per vial
Study: NCT00848003

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bifidobacterium animalis subsp. lactis strain BB-12
Description: Bifidobacterium animalis subsp. lactis (B. lactis) strain BB-12 (BB-12) probiotic supplemented yogurt, 4 ounces taken orally for 10 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Strawberry flavored yogurt
Study: NCT01593722

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diethylcarbamazine
Description: single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ivermectin
Description: single dose
Study: NCT00434343

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Global Therapeutic Massage (GTM)
Study: NCT02641899

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Oral atorvastatin 40 mg on Day 2 and Day 28

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lisinopril
Description: Oral lisinopril 20 mg on Day 2 and Day 28

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Description: Oral warfarin 25 mg on Day 2 and Day 28
Study: NCT00434343

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Myofascial physical therapy (MPT)
Description: Connective tissue manipulation to all body wall tissues of the abdominal wall, back, buttocks and thighs that clinically were found to contain connective tissue abnormalities and/or myofascial trigger point release to painful myofascial trigger points
Study: NCT02102360

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anorganic Bovine Bone
Description: used to improve periodontal regenerative procedures.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anorganic Bovine Bone
Description: used to improve periodontal regenerative procedures.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Enamel Matrix Derivative
Description: used to improve periodontal regenerative procedures.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Enamel Matrix Derivative
Description: used to improve periodontal regenerative procedures.
Study: NCT02992561

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: FORNET (adapted version)
Study: NCT04309071

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Description: Salivary insulin responses to a standardized mixed meal
Study: NCT03914300

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study: NCT03829670

Intervention type: DIAGNOSTIC_TEST
Intervention: Cytochrome P450 test
Description: Blood samples will be drawn for cytochrome P450 testing.
Study: NCT01511393

Intervention type: OTHER
Intervention: No treatment given
Description: None. Non-interventional study.
Study: NCT03333733

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HENRY
Description: HENRY is an 8-week programme delivered in Children's Centres, aiming to provide parents with skills and knowledge to support healthy lifestyles in preschool children and their families. It is currently delivered in \~ 35 local areas across England and Wales by trained health and community practitioners. Training includes:~Centre Level Training: to equip staff with knowledge and skills to promote and provide healthy nutrition within early years settings and support parents to provide healthy family lifestyles and nutrition for their families. The theoretical underpinning combines proven models of behaviour change including the Family Partnership Model, motivational interviewing and solution-focused support.~Practitioner Level Training: to deliver the 8-week HENRY programme, which aims to build parents' skills, knowledge and confidence to change old habits and provide healthier nutrition for their young children.
Study: NCT02641899

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: Oral digoxin 0.5 mg on Day 2 and Day 28
Study: NCT04481100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: itraconazole
Description: Oral administration of itraconazole twice daily concurrent with chemoradiation
Study: NCT03049631

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Raspberry and fructooligosaccharide
Description: Red raspberries (1 cup equivalent) with fructooligosaccharide (8 g)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Raspberry
Description: Red raspberries (1 cup equivalent)
Study: NCT03668015

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Xylitol then Sorbitol gum
Description: Xylitol gum contains 70% xylitol in addition to gum base, natural flavors, soy lecithin, gum arabic, titanium dioxide, carnuba wax. Sorbitol gum was similar except that xylitol was replaced by 63% sorbitol and 2% maltitol and aspartame was included.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sorbitol then Xylitol gum
Description: Sorbitol gum was similar except that xylitol was replaced by 63% sorbitol and 2% maltitol and aspartame was included. Xylitol gum contains 70% xylitol in addition to gum base, natural flavors, soy lecithin, gum arabic, titanium dioxide, carnuba wax.
Study: NCT00835588

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pantoprazole Sodium 40 mg delayed-release tablets
Description: 1 x 40 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PROTONIX® 40 mg delayed-release tablets.
Description: 1 x 40 mg
Study: NCT04096664

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SIMEOX
Description: Use without obligation, in autonomous and at home of the bronchial clearance device: SIMEOX
Study: NCT00829712

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmethylphenidate Hydrochloride
Description: 10 mg Tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmethylphenidate Hydrochloride
Description: 10 mg Tablet
Study: NCT03368443

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: treadmill training and overground gait training
Description: The participants will be randomized into two different groups, and they will receive treadmill and overground gait training in one or two rooms.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: treadmill training and overground gait training
Description: The participants will be randomized into two different groups, and they will receive treadmill and overground gait training in one or two rooms.
Study: NCT04311164

Intervention type: OTHER
Intervention: Questionnaire-based survey
Description: The online questionnaire-based survey is composed of multiple items including pre-coded (multiple choice) questions, dichotomous (yes/no) questions, rating scales and validated questionnaire scales to measure general and diabetes/insulin pump-specific behavior, psychological concepts and preferences.

Intervention type: OTHER
Intervention: No intervention given.
Description: No intervention was given.
Study: NCT01126463

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 188Re-SSS Lipiodol
Description: Hepatic Intra-Arterial Administration of radio-active lipiodol.
Study: NCT04159285

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EffEKTiv 2.0 group CBT as continuation treatment after ECT in depressed patients
Description: Group CBT with a maximum number of 8 participants. Group is half-open allowing a starting date right after completion of acute ECT treatment. Patients participate for 15 sessions, which are framed by 2 individual sessions before joining the group and one individual session at treatment end.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment as usual
Description: Can include continuation ECT, psychopharmacological treatment, individual psychotherapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment as usual
Description: Can include continuation ECT, psychopharmacological treatment, individual psychotherapy
Study: NCT01743898

Intervention type: DRUG
Intervention: Rivaroxaban
Description: Patients will continue on their Rivaroxaban dose as previously prescribed by their individual physician. No dose adjustments will be made for the purpose of this study.

Intervention type: OTHER
Intervention: no anticoagulation
Study: NCT04309968

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: SYHA1801
Description: Drug: SYHA1801 administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: SYHA1801
Description: Drug: SYHA1801 administered orally
Study: NCT00746850

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: early LC within 72 hours after the diagnosis with H (Harmonic)
Description: early laparoscopic cholecystectomy within 72 hours after the diagnosis of acute cholecystitis with H (Harmonic scalpel)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: early LC within 72 hours after the diagnosis with MD (Monopolar Diathermy)
Description: early laparoscopic cholecystectomy within 72 hours after the diagnosis of acute cholecystitis with MD (Monopolar Diathermy)
Study: NCT02914743

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: This intervention will involve a discussion intended to explore subjects' motivations to pursue dental care and empower them to visit a dentist upon release from the hospital.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: This intervention will involve a discussion intended to explore subjects' motivations to pursue dental care and empower them to visit a dentist upon release from the hospital.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dental cleaning
Description: This procedure will involve the removal of plaque and supragingival and subgingival calculus from the surfaces of the teeth.
Study: NCT05161962

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: One group received standard oral care.
Description: the effect of oral care given by two different methods on the development of ventilator-associated pneumonia in patients connected to mechanical ventilators.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: One group received standard oral care.
Description: the effect of oral care given by two different methods on the development of ventilator-associated pneumonia in patients connected to mechanical ventilators.

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: It was applied to the other group by aspiration.
Description: the effect of oral care given by two different methods on the development of ventilator-associated pneumonia in patients connected to mechanical ventilators.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: It was applied to the other group by aspiration.
Description: the effect of oral care given by two different methods on the development of ventilator-associated pneumonia in patients connected to mechanical ventilators.
Study: NCT00222846

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention control
Description: Participants attend 3 educational seminars, receive a lay diabetes journal, pedometer, and glucose monitoring supplies.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Behavioral intervention of diabetes self-management paired with PDA-based monitoring of dietary intake and physical activity. Participants also receive a pedometer and glucose self-monitoring supplies.
Study: NCT02805166

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-rhG-CSF
Study: NCT05361252

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SVV-guided fluid management
Description: fluid will be guided by value of stroke volume variation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SVV-guided fluid management
Description: fluid will be guided by value of stroke volume variation
Study: NCT03711253

Intervention type: DRUG
Group type: OTHER
Intervention: Bictegravir 50mg+Tenofovir AF 25 mg+emtricitabine 200 mg
Description: antiretroviral therapy
Study: NCT00473772

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DEBlue stent vs. Cypher stent
Description: DES vs. DEB with BMS

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DEBlue stent vs. Cypher stent
Description: DES vs. DEB with BMS
Study: NCT01896713

Intervention type: OTHER
Group type: OTHER
Intervention: MS3TMRI
Description: Multispectral 3 Tesla MRI imaging with contrast followed by biopsy
Study: NCT01937182

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Citalopram
Description: Citalopram 10-40 mg per day administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1/2-2 tablets per day with no intrinsic drug activity
Study: NCT02119988

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TIPS
Description: TIPS will be performed with a standard technique. TIPS revision will be planned if any evidence of shunt dysfunction is observed.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TIPS
Description: TIPS will be performed with a standard technique. TIPS revision will be planned if any evidence of shunt dysfunction is observed.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Variceal Embolization
Description: Embolization of gastroesophageal collaterals will be conducted via the same jugular vein before TIPS implantation. The major procedures includ (a) angiography of gastroesophageal collaterals after successful intrahepatic puncture of a branch of the portal vein and (b) embolization of gastroesophageal collaterals with coils of varying diameters, which result in the gastroesophageal collaterals disappearing at postembolization angiography.
Study: NCT04472039

Intervention type: DEVICE
Intervention: optical coherence tomography (OCT)
Description: OCT visualizes the retinal layers by backreflection of light
Study: NCT01909024

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Coil embolisation
Description: transjugular coil embolisation of pelvic veins

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endovenous treatment of leg recurrent varicose veins
Description: endovenous treatment of leg recurrent varicose veins

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: endovenous treatment of leg recurrent varicose veins
Description: endovenous treatment of leg recurrent varicose veins
Study: NCT04304209

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 130mg/m2, d1 q3w, in Capeox regimen (100mg/m2 when used cocurrently with radiotherapy), intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 130mg/m2, d1 q3w, in Capeox regimen (100mg/m2 when used cocurrently with radiotherapy), intravenous infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: 130mg/m2, d1 q3w, in Capeox regimen (100mg/m2 when used cocurrently with radiotherapy), intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 1000mg/m2, bid, qd1-14, q3w, in Capeox regimen, oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 1000mg/m2, bid, qd1-14, q3w, in Capeox regimen, oral administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: 1000mg/m2, bid, qd1-14, q3w, in Capeox regimen, oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: 200mg, d1 q3w, intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: 200mg, d1 q3w, intravenous infusion

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: neoadjuvant radiotherapy with 50Gy to GTV, 45Gy to CTV in 25 fractions.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiotherapy
Description: neoadjuvant radiotherapy with 50Gy to GTV, 45Gy to CTV in 25 fractions.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: total mesorectal excision
Description: total mesorectal excision after neoadjuvant treatment

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: total mesorectal excision
Description: total mesorectal excision after neoadjuvant treatment
Study: NCT01190787

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: velcade subcutaneous melphalan prednisone
Description: INDUCTION Velcade will be given as subcutaneous (SC) injection. Each cycle will be repeated every 28 days.~Melphalan will be given orally. Each cycle will be repeated every 28 days. Prednisone will be given orally.Each cycle will be repeated every 28 days. MAINTENANCE Velcade will be given a SC injection. Each cycle will be repeated every 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: velcade cyclophosphamide prednisone
Description: INDUCTION Velcade will be given as subcutaneous (SC) injection. Each cycle will be repeated every 28 days.~Cyclophosphamide will be given orally. Each cycle will be repeated every 28 days.~Prednisone will be given orally.Each cycle will be repeated every 28 days. MAINTENANCE Velcade will be given a SC injection. Each cycle will be repeated every 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: velcade prednisone
Description: INDUCTION Velcade will be given as subcutaneous (SC) injection. Each cycle will be repeated every 28 days.~Prednisone will be given orally.Each cycle will be repeated every 28 days. MAINTENANCE Velcade will be given a SC injection. Each cycle will be repeated every 28 days.
Study: NCT03433729

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient agenda form
Description: On arrival at the clinic patients are given an agenda form to prompt them to think about what issues they wished to discuss with their doctor. The form contains a prompt list of items they can tick, free space to write their own items, and a prompt to consider what is the most important issue for them and what they would like to happen before they leave their clinic appointment.
Study: NCT00804037

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Injection Snoreplasty
Description: Injection of 0,5 ml of the sclerosing agent into the soft palate (3 points)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Injection Snoreplasty
Description: Injection of 0,5 ml of the sclerosing agent into the soft palate (3 points)
Study: NCT04079673

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Patient controlled epidural analgesia
Description: Patient controlled epidural analgesia with marcaine 0.66mg/ml +fentanyl 1.75mcg/ml for postoperative pain control

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Intravenous patient controlled analgesia
Description: Intravenous patient controlled analgesia with morphine 1mg/ml for postoperative pain control
Study: NCT04459429

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Change of cannula size
Description: During nasal High Flow Therapy with fixed flow of 8 l/min, the cannula size will be changed from smaller-to-larger or larger-to-smaller

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Change of cannula size
Description: During nasal High Flow Therapy with fixed flow of 8 l/min, the cannula size will be changed from smaller-to-larger or larger-to-smaller
Study: NCT02315443

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nerinetide (NA-1)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo